Horizon Diagnostics Blog

Recent developments in targeting NTRK fusions for cancer therapeutics

Apr 27, 2018 3:24:21 PM No Comments

The NTRK Gene Family

Since the mid-80s, evidence has shown that gene fusions are implicated in cancer. With advances in Next Generation Sequencing (NGS) technology, the impact of gene fusions on driving cancers and how they act as potential therapeutic targets is quickly being revealed.

Read More Oncology Panels, NGS, Reference Standards, RNA, RNA fusions

Why You Should Use Cell Line-Derived Reference Material for NGS Oncology Assays

Apr 12, 2018 2:12:47 PM 1 Comment

 

We all know NGS analysis can be difficult to navigate. Not only is the human genome complex, but technical errors can occur throughout the entire workflow – from sample preparation, through sequencing and during analysis.

Thankfully, these technical errors can be mitigated by using high-quality reference material. Using the best standards for your assay will help both calibrate your NGS measurements and evaluate your diagnostic performance.

With advances in affordable technologies, there is now a multitude of reference types to choose from including patient material, cell line-derived standards and synthetic spike-ins. In this blog, we shine the spotlight on cell line-derived standards and the distinct advantages these have when used for NGS oncology assays.

Read More Oncology Panels, NGS, Reference Standards

10 Top Tips for Validating your NGS Assay

Feb 6, 2018 11:32:46 AM No Comments Comment

With new advances in technology, we’re now moving more towards large panel Next-Generation Sequencing (NGS) assays and whole exome (WES) and genome sequencing. NGS is gaining popularity thanks to the high-throughput capability and lower cost per sample.

However, validating these complex assays can be tricky, so we’ve compiled some top tips from industry guidelines* to help you...

Read More Oncology Panels, NGS, Reference Standards

Transitioning to NGS-based Oncology Panels

Jul 14, 2016 3:36:33 PM No Comments Comment

The high-throughput and increasingly affordable nature of Next-Generation Sequencing (NGS) has led to its expanded use in routine clinical procedures. The relative simplicity of targeted enrichment cancer panels (available from a number of commercial providers) allows routine laboratories to simultaneously analyze the coding (exonic) regions of multiple cancer-related key genes. Combine this with the statistic diagnostic testing now influencing over 70 percent of all health care decisions1, the setting up or transitioning to NGS-based oncology panels for labs has never been more important.

Read More Sanger Sequencing, Oncology Panels, NGS

Subscribe to Email Updates

RECENT POSTS